Fagron N.V.

Capital/Financing Update • May 1, 2014

Waregem (Belgium) / Rotterdam (The Netherlands)¹ , 30 April 2014 –Arseus announces today that there are no changes in the Guarantor List in accordance with the Guarantee Declaration dated 12 June 2012 regarding the € 225,000,000 4.75% Bond with maturity date 2 July 2017.

The list of Guarantors, in accordance with Article 10.4 of the Guarantee Declaration, is available at www.arseus.com.

In accordance with Condition 10 (b) of the Bonds a new Compliance Certificate is published. This Compliance Certificate is available at www.arseus.com.

In the event of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.

1/2

For further information: Marieke Palstra Director Investor Relations + 31 88 33 11 213 marieke.palstra@arseus.com

¹ This press release was sent out by Arseus NV and Arseus BV.

Arseus profile

Arseus is a scientific R&D company that supplies innovative solutions and concepts to professionals and institutions in the healthcare sector in 30 countries around the world. Arseus is made up of three divisions: Fagron is the global market leader in pharmaceutical compounding. Corilus develops and supplies medical specialists with unique integrated ICT solutions with substantial added value. Corilus is the market leader in selected segments in Belgium, France and the Netherlands. HL Technology develops and produces innovative precision components and orthopaedic tools for dental and medical professionals. The Belgian company Arseus NV is located in Waregem and is listed on NYSE Euronext Brussels and NYSE Euronext Amsterdam. The operational activities of the Arseus group are driven by the Dutch company Arseus BV. The head office of Arseus BV is located in Rotterdam.